<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part8">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>8</PartID>
        <PartNumber>Part VII</PartNumber>
        <PartSequenceNumber>8</PartSequenceNumber>
        <PartTitle>Drug Development</PartTitle>
        <PartChapterCount>3</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap36" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>36</ChapterID>
          <ChapterNumber>Chapter 36</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_36</ChapterDOI>
          <ChapterSequenceNumber>36</ChapterSequenceNumber>
          <ChapterTitle Language="En">Applications of Proteomics in Prostate Cancer</ChapterTitle>
          <ChapterFirstPage>407</ChapterFirstPage>
          <ChapterLastPage>417</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>8</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Mitchell</GivenName>
                <FamilyName>Gross</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Edward</GivenName>
                <GivenName>Macrohon</GivenName>
                <FamilyName>Nepomuceno</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff1_36" CorrespondingAffiliationID="Aff1_36">
              <AuthorName DisplayOrder="Western">
                <GivenName>David</GivenName>
                <GivenName>B.</GivenName>
                <FamilyName>Agus</FamilyName>
              </AuthorName>
              <Contact>
                <Email>agus@usc.edu</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_36">
              <OrgDivision>USC Westside Prostate Cancer Center</OrgDivision>
              <OrgName>Keck School of Medicine of USC</OrgName>
              <OrgAddress>
                <City>Beverly Hills</City>
                <State>CA</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_36" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Prostate-specific antigen (PSA) is the most commonly used circulating protein biomarker, which guides the diagnosis and treatment of prostate cancer. However, limitations in sensitivity and specificity limit utility of PSA when used as a diagnostic marker in screening population or as a prognostic, theragnostic, or surrogate biomarker in patients with recurrent or advanced prostate cancer. Accordingly, there is a need to discover new biomarkers to improve diagnosis, risk stratification, and therapeutic monitoring in prostate cancer. Proteomics, as an emerging technology, offers great promise in providing the cancer research community with biomarkers to guide therapeutic decision-making. However, caution must be used as new biomarkers are discovered and subject to appropriate validation before they can be applied to mainstream clinical settings.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Proteomic</Keyword>
            <Keyword>Mass spectrometry</Keyword>
            <Keyword>Biomarker (diagnostic, prognostic, predictive, pharmacogenomic)</Keyword>
            <Keyword>Theragnostic</Keyword>
            <Keyword>Prostate-specific antigen</Keyword>
            <Keyword>Immunohistochemistry</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Prostate cancer (CaP) results from alterations and deregulations in control of growth, motility, and survival. It is generally believed that a more complete and fundamental understanding of the processes, which are altered in cancer, can be uncovered at a molecular level and that this insight will lead to new, improved, and personalized treatment approaches.</Para>
            <Para TextBreak="No">Proteomics denotes the large scale identification and monitoring of proteins in biologic systems. A fundamental goal of proteomic research is to uncover the basic mechanisms and pathways that contribute to the process of transformation. Over the last few decades, proteomic technologies have been applied in an attempt to understand complex biologic processes including prostate cancer. In general, these approaches have not yet been successful at contributing fundamental insights into clinical disease. Most recently, technological advances have provided new and improved tools to allow unprecedented sensitivity, quantification, and completeness for proteomic analysis of complex biologic tissues. Moreover, the integration of proteomic with genomic and transcription profiling technologies provides an unprecedented complete and complex data set to understand the fundamental processes, which underlie the development and progression of prostate cancer and therapeutic response. We focus on the application of these technologies, which may fundamentally change the care of prostate cancer.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Cancer Biomarkers Overview</Heading>
            <Para TextBreak="No">Biomarkers are quantifiable measurements, which can be used as indicators of an underlying biologic process [<CitationRef CitationID="CR1_36">1</CitationRef>]. For cancer biomarkers, in particular, there is a developing framework, which separates biomarkers according to potential utilities in terms of diagnostic, prognostic, predictive, and therapeutic monitoring (Table <InternalRef RefID="Tab1">36.1</InternalRef>) [<CitationRef CitationID="CR2_36">2</CitationRef>, <CitationRef CitationID="CR3_36">3</CitationRef>]. The promise of individualized therapy hinges on the use of predictive biomarkers to direct therapies in specific patients. Predictive biomarkers represent a relatively new and increasingly important paradigm in oncology as molecular biomarkers are directly linked to cancer biology and molecular therapeutics. However, there are only a few examples of predictive biomarkers in oncology. Well-studied examples include amplification of the human epidermal growth factor-2 (HER2) oncogene and the utility of a HER2-directed antibody (trastuzumab), expression of the estrogen receptor protein with estrogen-inhibiting therapies in breast cancer, and the presence of the BCR-ABL oncogenic translocation and the activity of ABL-tyrosine kinase inhibitors in chronic myelogenous leukemia [<CitationRef CitationID="CR4_36">4</CitationRef>, <CitationRef CitationID="CR5_36">5</CitationRef>]. More recently, some molecular characteristics have been identified, which function as predictive biomarkers in other cancers including the presence of epidermal growth factor receptor (EGFR) mutations with EGFR tyrosine kinase inhibitors in lung cancer and <Emphasis Type="Italic">KRAS</Emphasis> mutations with resistance to EGFR antibody in colon cancer [<CitationRef CitationID="CR6_36">6</CitationRef>, <CitationRef CitationID="CR7_36">7</CitationRef>]. Multi-gene signatures have also been developed as predictive markers for patients with breast cancer [<CitationRef CitationID="CR8_36">8</CitationRef>]. Development of predictive biomarkers represents an important unmet need for prostate cancer.<Table Float="Yes" ID="Tab1">
                <Caption Language="En">
                  <CaptionNumber>Table 36.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Classification of cancer biomarkers</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="2">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Diagnostic</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Definitively establish the presence of cancer</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Prognostic</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Predict the probably outcome of cancer regardless of therapy; may be used to stratify patients for more aggressive therapy</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Prediction/theragnostic</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Predict response to a specific therapy</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Pharmacodynamic/therapeutic monitoring</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Determine whether a therapy is having the intended effect on the disease based on changes over time; “pharmacodynamic marker that therapy is affecting its intended target to produce the desired result”</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry nameend="c2" namest="c1">
                        <SimplePara>Adapted from Table 1.1 [<CitationRef CitationID="CR2_36">2</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
              </Table>
            </Para>
            <Para TextBreak="No">For prostate and other cancers, currently used prognostic biomarkers are relatively coarsely defined clinico-pathologic variables such as clinical stage, histologic subtype, and performance status. The focus of much of the previous research efforts has been to develop tissue or blood-based prognostic biomarkers for prostate cancer. In some studies, there is a suggestion that these markers may add to standard prognostic biomarkers such as prostate-specific antigen (PSA), Gleason grade, and tumor stage. However, most of these reports are limited to single cohorts and have not been validated in multi-institution studies. Further, many of these tissue or blood-based markers do not have direct relevance in treatment decision making (i.e., they are not predictive). Taken together, these considerations have prevented the routine application of protein-based biomarkers, other than PSA, from entering routine clinical practice.</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>Current Status of Tissue-Based Protein Biomarkers</Heading>
            <Section2 ID="Sec4">
              <Heading>Tissue-Based Diagnostic Markers</Heading>
              <Para TextBreak="No">Classical histology (tissue morphology based hematoxylin and eosin staining) is the “gold standard” diagnostic biomarker used to differentiate cancer from normal tissue. Ultimately, histology depends on patterns and differential staining of proteins with eosin and nucleic acid with hematoxylin. Techniques to examine protein expression patterns in tissue based on immunohistochemistry (IHC) are well-established in anatomic pathology. A common use of IHC in prostate cancer is to confirm a diagnosis of CaP in small areas of atypical glands submitted in limited tissue samples obtained from routine prostate biopsy. Loss of a basal cell marker (p63 or high molecular weight cytokeratin) along with increased expression of a marker for dysplastic or cancerous epithelium (alpha-methylacyl-CoA racemase) is helpful to distinguish cancerous from normal acini [<CitationRef CitationID="CR9_36">9</CitationRef>]. Occasionally, IHC is used to confirm the tissue of origin in locally advanced or metastatic CaP [<CitationRef CitationID="CR10_36">10</CitationRef>]. Generally, metastatic prostate cancer expresses androgen receptor (AR), prostate acid phosphotase (PAP), and PSA.</Para>
            </Section2>
            <Section2 ID="Sec5">
              <Heading>Tissue-Based Prognostic Markers</Heading>
              <Para TextBreak="No">The Gleason grading system provides important prognostic information in patients with prostate cancer and is commonly used (along with clinical stage and serum PSA) to guide initial therapeutic decisions for patients with prostate cancer [<CitationRef CitationID="CR11_36">11</CitationRef>–<CitationRef CitationID="CR15_36">15</CitationRef>]. Prognostic nomograms incorporating these and other clinical factors have been widely reported and used to predict progression-free interval following primary therapy with surgery or radiation [<CitationRef CitationID="CR16_36">16</CitationRef>].</Para>
              <Para TextBreak="No">There are a few reports describing the utility of gene expression studies as a prognostic biomarker in prostate cancer. Approaches based on gene expression analysis in fresh frozen tissue have shown preliminary evidence of producing prognostic information for patients with CaP [<CitationRef CitationID="CR17_36">17</CitationRef>–<CitationRef CitationID="CR19_36">19</CitationRef>]. These studies share a similar experimental approach in that microarrays are used to compare gene expression with pathologic variables in primary prostate cancer specimens. Perhaps due to small methodological variations and other technical limitations, no gene or protein prognostic marker was shared by these (and subsequent) studies. However, individual studies did contribute specific information about tissue-based prognostic markers. Lapointe et al. showed that expression of MUC1 and AZGP1 (zinc-α-2-glycoporotein) was associated with an increased and decreased risk of recurrence, respectively [<CitationRef CitationID="CR17_36">17</CitationRef>]. Similarly, True et al. identified increased protein expression of monoamine oxidase A (<Emphasis Type="Italic">MAOA</Emphasis>), and defender against death (DAD1) in higher grade prostate cancers [<CitationRef CitationID="CR18_36">18</CitationRef>]. Perhaps attributed to limitations in the immune reagents, quantization, and sample variability, none of these IHC-based markers are used in clinical practice to guide the care of patients with prostate cancer.</Para>
              <Para TextBreak="No">Other studies have explored potential utility for tissue-based prognostic markers with IHC based on putative roles and function derived from the preclinical and related studies (summarized in Table <InternalRef RefID="Tab2">36.2</InternalRef>) [<CitationRef CitationID="CR20_36">20</CitationRef>]. Individually, these studies produce interesting insights into processes that contribute to the development and progression of prostate cancer. However, many studies are based on IHC-techniques, which are difficult to standardize or have not been validated in subsequent studies or with larger cohorts of unselected patients. More importantly, these prognostic markers have not been directly linked to treatment decision making (i.e., they are not predictive biomarkers). Therefore, most of these prognostic markers have not entered routine clinical practice.<Table Float="Yes" ID="Tab2">
                  <Caption Language="En">
                    <CaptionNumber>Table 36.2</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Examples of tissue-based prognostic protein biomarkers</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="5">
                    <colspec colname="c1" colnum="1"/>
                    <colspec colname="c2" colnum="2"/>
                    <colspec colname="c3" colnum="3"/>
                    <colspec colname="c4" colnum="4"/>
                    <colspec colname="c5" colnum="5"/>
                    <thead>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Biomarker</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Source</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Technique</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Comment</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>References</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry colname="c1">
                          <SimplePara>p27</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Tissue</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>IHC</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Cyclin-dependent kinase inhibitor involved with cell cycle arrest and apoptosis
</SimplePara>
                          <SimplePara>Low levels of p27 expression associated with adverse prognosis in patients undergoing prostatectomy</SimplePara>
                          <SimplePara>In patients with positive margins, a low p27 is associated with a higher risk of recurrence</SimplePara>
                          <SimplePara>Levels at the time of prostate biopsy are associated with time to PSA failure</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>[<CitationRef CitationID="CR21_36">21</CitationRef>, <CitationRef CitationID="CR22_36">22</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Caveolin-1</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Tissue,</SimplePara>
                          <SimplePara>Serum</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>IHC
</SimplePara>
                          <SimplePara>Sandwich immunoassay</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Structural protein involved in regulation of membrane trafficking, cell adhesion, and signaling
</SimplePara>
                          <SimplePara>High expression correlates with Gleason score, positive surgical margins, and lymph node involvement</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>[<CitationRef CitationID="CR23_36">23</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Androgen receptor (AR)</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Tissue</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>IHC</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>High levels of AR expression in prostatectomy samples correlate with clinical stage, lymph node status, extracapsular extension, seminal vesicle invasion, and Gleason score
</SimplePara>
                          <SimplePara>High AR expression was predictive of higher probability of recurrence</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>[<CitationRef CitationID="CR24_36">24</CitationRef>–<CitationRef CitationID="CR26_36">26</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Estrogen receptor-β (ERβ)</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Tissue</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>IHC</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Expression may be lower in some high grade prostate cancer
</SimplePara>
                          <SimplePara>High expression may be related to shorter progression free survival</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>[<CitationRef CitationID="CR27_36">27</CitationRef>, <CitationRef CitationID="CR28_36">28</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Ki-67</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Tissue</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>IHC</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Marker for cellular proliferation
</SimplePara>
                          <SimplePara>High expression correlates with decreased progression free survival in postradiation setting</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>[<CitationRef CitationID="CR29_36">29</CitationRef>–<CitationRef CitationID="CR31_36">31</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                </Table>
              </Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec6">
            <Heading>Current Status of Blood-Based Protein Biomarkers</Heading>
            <Para TextBreak="No">Blood is a particularly attractive tissue to develop clinically important biomarkers, especially for patients with prostate cancer. The utility of tissue-based markers may be limited by the heterogeneity of prostate epithelial cells often mixed with normal glands and stroma. Especially for IHC-based techniques, heterogeneous expression patterns and difficulties in standardization present significant challenges to validating important biomarkers using these techniques. Further, direct access to cancer tissue is particularly limited in patients with prostate cancer as often the only tissue available for subsequent analysis are core biopsies obtained many years before development of more aggressive, metastatic disease. The promise of blood-based biomarkers addresses many of these limitations. Blood may be repeatedly sampled in many stages of the disease, and large collections of blood exist to perform biomarker discovery and validation experiments for diagnostic and prognostic studies. Relatively standardized collection and processing techniques applying to blood and blood-based markers may not be as liable and may be more robust than tissue-based studies.</Para>
            <Para TextBreak="No">Aside from PSA, other blood borne protein markers have been studied as diagnostic, prognostic, and predictive biomarkers in prostate cancer [<CitationRef CitationID="CR32_36">32</CitationRef>]. Some studies report that levels of human glandular kallikrein (hK2, a serine-protease related to PSA) or levels of antigen derived from prostate cancer nuclear matrix (early prostate cancer antigen-2, EPCA-2) may add to the diagnostic accuracy of serum PSA [<CitationRef CitationID="CR29_36">29</CitationRef>–<CitationRef CitationID="CR31_36">31</CitationRef>, <CitationRef CitationID="CR33_36">33</CitationRef>, <CitationRef CitationID="CR34_36">34</CitationRef>]. Other studies have focused on blood borne prognostic and predictive markers. Chromogranin A (CGA) and neuron-specific enolase (NSE) represent neuroendocrine proteins, which are expressed, at variable levels, in primary and metastatic prostate cancer deposits. Both markers are commonly elevated in the blood in recurrent prostate cancer and have shown to add independent prognostic information to models, which also incorporate PSA [<CitationRef CitationID="CR35_36">35</CitationRef>–<CitationRef CitationID="CR38_36">38</CitationRef>]. As metastatic involvement of bone is one of the most common clinical scenarios in patients with advanced prostate cancer, bone markers have been studied as markers that predict the development of metastatic disease. In a study that compared the accuracy of ten bone metabolism markers as diagnostic and predictive marker, osteoprotegerin (OPG) had high diagnostic and prognostic validity of all markers tested, and remained significant in multivariate models [<CitationRef CitationID="CR39_36">39</CitationRef>]. Total or bone-specific alkaline phosphatases are prognostic in advanced prostate cancer [<CitationRef CitationID="CR40_36">40</CitationRef>–<CitationRef CitationID="CR42_36">42</CitationRef>]. Other prognostic models for advanced CaP have shown that elevations in relatively nonspecific immune markers (such as lactate dehydrogenase C-reactive protein, or interleukin-6) are associated with poor outcomes [<CitationRef CitationID="CR40_36">40</CitationRef>–<CitationRef CitationID="CR45_36">45</CitationRef>].</Para>
            <Section2 ID="Sec7">
              <Heading>PSA as an Example of a Widely Used Blood-Based Biomarker</Heading>
              <Para TextBreak="No">PSA is an androgen-regulated secreted protein, which is expressed by both normal and malignant prostate epithelial cells and is widely used as a serum marker for prostate cancer [<CitationRef CitationID="CR46_36">46</CitationRef>]. As a diagnostic marker, PSA elevation (≥4 ng/mL) is a relatively sensitive (∼80–90%) biomarker [<CitationRef CitationID="CR47_36">47</CitationRef>–<CitationRef CitationID="CR49_36">49</CitationRef>]. However, as PSA is also produced by noncancerous prostate epithelium and levels can be elevated by benign prostate hypertrophy, prostate inflammation, and other factors, PSA as a diagnostic biomarker lacks specificity [<CitationRef CitationID="CR46_36">46</CitationRef>]. Depending on population age and other risk factors, occult prostate cancers may be found in approximately 25% of patients with normal PSA levels (≤4 ng/mL) [<CitationRef CitationID="CR50_36">50</CitationRef>]. Insights into the normal biology of PSA have led to studies that try to improve on the sensitivity and specificity of PSA as a diagnostic biomarker. In prostate cancer cells, disruption of the basement membrane allows the PSA molecule and its modified forms to be more readily released directly into the blood stream. With less exposure to the seminal proteases present in the lumen, fewer cleaved PSA products are available in the serum. Thus, the ratio of free PSA to total PSA (fPSA/tPSA) or “PSA index” is lower in patients with prostate cancer and can be used to distinguish cases with intermediate PSA levels (i.e., 4–10 ng/mL) [<CitationRef CitationID="CR46_36">46</CitationRef>]. Various truncated forms of the proPSA have also been suggested as potential biomarkers for patients with prostate cancer, which could increase the specificity of PSA testing [<CitationRef CitationID="CR51_36">51</CitationRef>].</Para>
              <Para TextBreak="No">PSA is also widely used as a prognostic biomarker for many stages and forms of prostate cancer. At the time of diagnosis, many risk prediction models routinely identify pretherapy PSA level as an independent factor, which predicts progression free survival [<CitationRef CitationID="CR11_36">11</CitationRef>, <CitationRef CitationID="CR13_36">13</CitationRef>–<CitationRef CitationID="CR15_36">15</CitationRef>]. Most, but not all, patients with recurrent CaP demonstrate elevated levels of PSA. For recurrent prostate cancer, PSA levels contribute to multivariable models to predict survival for castration-resistant prostate cancer (CRPC) [<CitationRef CitationID="CR41_36">41</CitationRef>, <CitationRef CitationID="CR42_36">42</CitationRef>]. The most important use of PSA in recurrent prostate cancer is to monitor therapy response. As PSA is an androgen-regulated secreted protein, decreases in PSA levels are expected following androgen-deprivation therapy. Further, PSA kinetics and the extent of the PSA nadir are useful ways to monitor therapy response [<CitationRef CitationID="CR52_36">52</CitationRef>–<CitationRef CitationID="CR54_36">54</CitationRef>]. For most patients, a PSA elevation despite androgen-deprivation therapy is a harbinger of androgen-independent progression. For CRPC, changes in PSA levels, such as a confirmed PSA decline of 50% compared with baseline, are commonly incorporated into reports from HRPC therapeutic trials, based on standardized reporting guidelines [<CitationRef CitationID="CR55_36">55</CitationRef>]. Most recently, a 30% decrease in PSA in response to docetaxel-based first-line chemotherapy for CRPC has been shown to function as a surrogate for overall survival in this population [<CitationRef CitationID="CR40_36">40</CitationRef>].</Para>
              <Para TextBreak="No">Although PSA is a widely used diagnostic, prognostic, and activity marker for prostate cancer, a significant limitation remains such that changes in PSA levels cannot be used to predict therapy. Further, decreases of PSA in response to therapy remain as a yet not validated surrogate for overall survival in response to taxane-based chemotherapy.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec8">
            <Heading>Overview of Proteomic Technologies</Heading>
            <Para TextBreak="No">Proteomics refers to the study of the total set of proteins present in a complex biologic tissue at a particular point in time. Depending on the experimental question, subproteomes can be defined to include the sets of all proteins expressed in an organism, tissue (blood or prostate), or isolated cells. Subproteomes can also be defined based on protein location (cytoplasmic, nuclear, secreted), function (tyrosine kinases), and modifications (phosphorylation, glycosylation). Advancements in the technology of mass spectrometry are providing a method of high-throughput protein identification and quantification to present a complete representation of protein expression from many types of samples. As with other emerging technologies, attention must be paid to method development as small differences in technique may produce large differences in results. In general, the proteomic methods can be divided into four main steps: sample preparation, protein separation, protein identification, and quantification.</Para>
            <Section2 ID="Sec9">
              <Heading>Sample Preparation</Heading>
              <Para TextBreak="No">Sample preparation is one of the most important, and often most overlooked, part of any proteomic experiment. The choice of tissue to be analyzed is the first critical decision point in any such study. Analysis may focus on an individual cell type, tumor tissue, or the whole organism. Focus on a pure cell population may be important for experimental purposes, but complex isolation techniques may limit the applicability of the results to clinical laboratories. Studies that begin with minimally processed tissues, such as tumor samples, may have to overcome noninformative levels of normal proteins to detect small changes in important proteins in a subset of critical cells. Blood may be a particularly useful protein-rich tissue to be analyzed as it continuously samples all tissues in the body.</Para>
              <Para TextBreak="No">Protein stability is also an important consideration. Some proteins are inherently stable and may remain unchanged at ambient temperatures for long periods of time, while other proteins, and in particular posttranslational modifications, are particularly labile [<CitationRef CitationID="CR56_36">56</CitationRef>]. The action of proteases and other enzymes present in biologic tissue may also obscure important biologic variations in protein content. Sample preparation protocols most balance a need to maintain and preserve protein complexity with an understanding of practical considerations and potential clinical utility. For example, the semi-standardized collection and processing of blood into plasma may preserve protein content because EDTA-mediated inhibition of proteases [<CitationRef CitationID="CR57_36">57</CitationRef>]. However, more detailed proteomic investigations are starting to show that relatively minor variations in variables such as “clot time,” “storage temperature,” and number of “freeze thaw cycles” may produce important differences in protein content [<CitationRef CitationID="CR58_36">58</CitationRef>, <CitationRef CitationID="CR59_36">59</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec10">
              <Heading>Protein/Peptide Separation</Heading>
              <Para TextBreak="No">One of the primary challenges in analyzing any proteomic experiment is the vast range of protein concentrations found in biologic systems. Proteins comprise both the relatively invariant structural elements in cells and tissues as well as highly variable and liable elements, which direct major cellular processes. The problem presented by the range of protein concentrations found in biologic tissue is best demonstrated in blood (plasma). Concentrations for blood-resident proteins range from ∼50 g/L for albumin down to ∼10<Superscript>−8</Superscript>–10<Superscript>−9</Superscript> g/L for many cytokines and peptide hormones; a concentration range that spans about ten orders of magnitude [<CitationRef CitationID="CR60_36">60</CitationRef>]. Unfortunately, the resolving power of most mass spectrometers only spans about 4–5 orders of magnitude. Therefore, in the absence of any fractionation, the ability to detect and quantify proteins of mid to lower levels of abundance is severely limited by high-abundant and relatively noninformative proteins.</Para>
              <Para TextBreak="No">A variety of approaches have been developed to address the problem of sample fractionation for proteomic analysis. For many years, two-dimensional gel chromatography, which separates proteins based on electrical charge and size, has commonly been used in front of proteomic analysis [<CitationRef CitationID="CR61_36">61</CitationRef>]. More recently, liquid chromatography (LC) has become a standard method for proteomic separation. LC-based separation protocols are appealing as they effectively subfractionate a complex sample into a series of much simpler samples, which are sequentially presented to the mass spectrometer. LC is also convenient as it can be used in line with many mass spectrometers. A somewhat standardized approach includes a proteolysis step, with trypsin, to produce protein fragments (peptides) within a relatively narrow size range (typically ∼10 amino acids or about 1,000–2,000 Da). Depending on the goals of the experiment, LC-MS protocols may be optimized to focus proteomic analysis on the sub-proteomes of specific biologic interest. For unbiased proteomics-based biomarker discovery (short gun proteomics), the LC-MS setup has commonly been used as it can produce the most complete representation of clinical tissues to date [<CitationRef CitationID="CR62_36">62</CitationRef>, <CitationRef CitationID="CR63_36">63</CitationRef>].</Para>
              <Para TextBreak="No">Another approach to address the problem of dynamic range and sensitivity is to use affinity methods to enrich, or deplete, samples (prior to trypsinization) to focus proteomic techniques on the most informative proteins. Immuno-affinity columns have been developed to deplete high-abundance protein from blood including albumin, immunoglobin, and transferring [<CitationRef CitationID="CR64_36">64</CitationRef>–<CitationRef CitationID="CR66_36">66</CitationRef>]. Conversely, affinity methods may be used to enrich samples for proteins of interest. For example, phosphorylated species can be isolated based on their differential affinity to immobilized metal species and phosphotyrosine-specific antibodies [<CitationRef CitationID="CR67_36">67</CitationRef>, <CitationRef CitationID="CR68_36">68</CitationRef>]. Similar work was recently developed for isolating and analyzing glycosylated species in blood [<CitationRef CitationID="CR69_36">69</CitationRef>]. Protein glycosylation, and in particular N-linked glycosylation, is prevalent in proteins destined for extra cellular environments. These include proteins on the extracellular side of the plasma membrane, secreted proteins, and proteins contained in body fluids (e.g., blood serum). Therefore, many commonly used cancer biomarkers (including PSA, CA-125, and alpha-fetoprotein) are glycosylated.</Para>
            </Section2>
            <Section2 ID="Sec11">
              <Heading>Protein Identification and Protein Quantification</Heading>
              <Para TextBreak="No">Mass spectrometry (MS) characterizes the composition of a sample mixture based on the mass to charge ratio (<Emphasis Type="Italic">m</Emphasis>/<Emphasis Type="Italic">z</Emphasis> ratio). MS instruments require an ionizing source to produce gas-phase ions. The two common forms of ionization are as follows: electrospray ionization (ESI), in which peptides in a liquid sample are converted to gas-phase ions through high voltage, heat, and drying gases; and matrix-assisted laser desorption ionization (MALDI), in which ions are produced when peptides are mixed with a photoreactive matrix followed by laser irradiation [<CitationRef CitationID="CR70_36">70</CitationRef>, <CitationRef CitationID="CR71_36">71</CitationRef>]. An advantage of ESI is that the input may include direct infection of the efflux from a liquid chromatographic prefractionation step (such as LC) and is amenable to high-throughput configurations. Disadvantages of MALDI are that neither it generally may not be used “in-line” with other fractionation techniques nor can the process be easily automated for high-throughput applications. Following ionization, peptide/proteins are analyzed to determine their <Emphasis Type="Italic">m</Emphasis>/<Emphasis Type="Italic">z</Emphasis> ratio. Common detection techniques are time-of-flight (TOF), which measures the time it takes for the ion to travel from the ion source to the detector plate, (more massive objects take more time) and Fourier transform-ion cyclotron resonance (FT-ICR), which analyzes the electrical field produced by ions orbiting in a strong magnetic field (more massive ions circulate more slowly) [<CitationRef CitationID="CR72_36">72</CitationRef>]. MS-based technologic advances are such that the most accurate instruments commonly used in proteomic experiments (FT-ICR) can determine the mass of a typical peptide (∼1,000 Da) to within 0.001 Da (∼10 parts per million) [<CitationRef CitationID="CR71_36">71</CitationRef>]. Many mass spectrometers are capable of “tandem operation” (MS/MS). In this configuration, parent ions can be selected and concentrated by a magnetic quadropole and then fragmented to produce daughter ions; the pattern and weights of these ions can be used to deduce the precise amino acid sequence of the parent peptide [<CitationRef CitationID="CR73_36">73</CitationRef>]. Together, the accuracy and resolution provided by modern MS instruments allows for an increasingly complete identification of all proteins present in biologic samples [<CitationRef CitationID="CR74_36">74</CitationRef>].</Para>
              <Para TextBreak="No">Protein quantification presents another important challenge for MS-based techniques. In most configurations, the size of the <Emphasis Type="Italic">m</Emphasis>/<Emphasis Type="Italic">z</Emphasis> peak is qualitatively related to the abundance of the underlying peptide. However, experimental variability including that produced by prefractionation methods, the abundance of other ion species, among others precludes a precise measurement of quantization from standard MS data. In many experimental situations, one is most interested in comparing protein levels between samples, rather than deriving an absolute quantity. Isotope and dye-based labeling protocols have been developed to allow pair-wise comparison of biologic samples [<CitationRef CitationID="CR75_36">75</CitationRef>, <CitationRef CitationID="CR76_36">76</CitationRef>].</Para>
              <Para TextBreak="No">Selective reaction monitoring and multiple reaction monitoring (SRM/MRM) is a technique for “targeted proteomics,” which combines protein identification and quantization into a single high-throughput experimental configuration. A fundamental principle of MS instruments is that precision improves with the square root of the number of ions measured [<CitationRef CitationID="CR77_36">77</CitationRef>]. Triple-quadrapole MS instruments allow for selective retention of ions within a precise mass/charge window for subsequent analysis. In this way, the accuracy of measurement is greatly enhanced. In all analytical chemistry, simultaneous detection and quantization of an internal standard along with the analyte of interest is desirable as a way to standardize for systematic measurement errors. The mass accuracy of triple-quadrapole MS instruments allows for the addition of known amounts of chemically similar peptides with different mass/charge ration via the incorporation of unnatural isotope abundances. These isotopically labeled peptides can be used as internal standards to provide accurate quantization of samples and to account for nonstochastic differentiation in sample preparation and ionization efficiencies. Lastly, SRM can unambiguously identify target peptides based on fragmentation signatures. Therefore, SRM utilizes the capability of triple-quadropole mass spectrometers to select for ions of interest (to improve precision) with the addition of isotope-substituted monitor peptides (for quantization) and CID (for identification). In this way, SRM assays can be designed to monitor analyte peptides with high precision (CV&lt;10%). SRM assays (ion selection and monitor peptides) are often combined to produce multiple reaction monitoring and provide accurate measurements of abundances of multiple proteins. Recently, several groups have reported the limit of detection for proteins (including PSA) spiked into human serum in the 1–10 ng/mL range by combining prefractionation with MRM [<CitationRef CitationID="CR78_36">78</CitationRef>, <CitationRef CitationID="CR79_36">79</CitationRef>].</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec12">
            <Heading>Examples of Proteomic Applications for Prostate Cancer</Heading>
            <Para TextBreak="No">A number of groups have reported preliminary results, which seek to apply serum proteomic analysis to develop an improved screening test for prostate and other cancers [<CitationRef CitationID="CR80_36">80</CitationRef>–<CitationRef CitationID="CR82_36">82</CitationRef>]. These studies applied a low-resolution form of whole protein serum profiling based on surface-enhanced laser desorption ionization time-of-flight (SELDI-TOF) spectrometry. SELDI is a modification of MALDI, which seeks to streamline protein separation with analysis in a high-throughput system. Analytes are placed directly onto metal plates (chips) coated with substances to mimic the separation properties of substances such as ion-exchange resins, hydrophobic separation (C4, C18), immobilized metal surfaces, among others. The chips are then washed (to remove unbound material), matrix is added, and bound proteins are analyzed by TOF MS. There have been some reported successes with this technology in proteomic analysis of blood, including a use in prostate cancer diagnostics [<CitationRef CitationID="CR82_36">82</CitationRef>]. Significant efforts have been undertaken in an attempt to standardize and validate SELDI-TOF for early cancer diagnosis [<CitationRef CitationID="CR83_36">83</CitationRef>]. However, the SELDI-TOF techniques utilized are limited by the small dynamic range, poor mass range (proteins only approximately 5–30 kDa), and poor ability to perform protein identification and validation. In addition, reanalysis of some of the original SELDI-TOF data revealed the presence of significant nonbiologic experimental bias between subjects with cancer and controls, which may have been the result of differences in specimen handling before MS data was collected [<CitationRef CitationID="CR84_36">84</CitationRef>]. Overall, these and other issues have significantly decreased the enthusiasm for utilizing SELDI-TOF to develop prostate cancer biomarkers.</Para>
            <Para TextBreak="No">A very active area for the application of proteomics for the study of prostate cancer involves target identification toward discovering prognostic and predictive biomarkers. Proteins secreted or shed by prostate cancer cells grown in tissue culture may reflect circulating markers, which directly reflect the status of prostate cancer cells in patients [<CitationRef CitationID="CR85_36">85</CitationRef>]. Proteomic techniques can be used to identify and quantify these proteins in the hopes discovering clinically useful biomarkers for patient care. In a study utilizing quantitative proteomics based on an isotope-coded affinity tag (ICAT) technique, Martin et al. identified over 600 proteins present in the conditioned media from the LNCaP human prostate cancer cell line [<CitationRef CitationID="CR86_36">86</CitationRef>]. Interestingly, most of the proteins identified in the media were predicted to be present inside the cells (cytoplasmic or nuclear), based on annotated databases, while only about a quarter of proteins were predicted to be expressed in compartments directly exposed to the extracellular space (as cell-bound or secreted proteins). The study also identified about 50 novel proteins regulated by androgen-stimulation. Recently, we reported the results utilizing SELDI-TOF to study androgen-regulated proteins utilizing a similar experimental design. In this study, we identified beta-2-microglobulin (β2M) as an androgen-regulated secreted protein, which is highly expressed in prostate cancer cells and tissues, and is elevated in the serum of prostate cancer patients [<CitationRef CitationID="CR87_36">87</CitationRef>]. Discovery efforts have applied proteomic technologies to study important therapeutic targets include the androgen receptor and microtubules [<CitationRef CitationID="CR88_36">88</CitationRef>, <CitationRef CitationID="CR89_36">89</CitationRef>]. More generally, proteomic techniques are well suited to study specific cancer phenotypes such as therapy resistance. A particularly promising approach is to combine proteomic and genomic analyses to understand entire biologic networks, which may underlie a disease-specific phenotype [<CitationRef CitationID="CR90_36">90</CitationRef>, <CitationRef CitationID="CR91_36">91</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec13">
            <Heading>Summary</Heading>
            <Para TextBreak="No">Technologic development and maturation of proteomic technologies is poised to give clinical sciences important analytical tools to study human disease. There is a high likelihood that a combination of protein identification and quantization tools, including IHC and MS-based technologies to provide individualized information, reflect the molecular characterization of cancer. As these assays are developed, attention must be focused on issues such as reproducibility and validation to ensure the results of these studies will have maximal applicability to patient care. The success of these approaches may lead to better diagnostic, prognostic, and predictive markers to direct therapy for prostate cancer.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_36.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_36">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <InstitutionalAuthorName>Biomarkers Definitions Working Group</InstitutionalAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Biomarkers and surrogate endpoints preferred definitions and conceptual framework</ArticleTitle>
                <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                <VolumeID>69</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>89</FirstPage>
                <LastPage>95</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1067/mcp.2001.113989</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89–95.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_36">
              <CitationNumber>2</CitationNumber>
              <BibUnstructured>Patlak M, Nass SJ, National Cancer Policy Forum (U.S.), United States. Department of Health and Human Services. Developing biomarker-based tools for cancer screening, diagnosis, and treatment: the state of the science, evaluation, implementation, and economics: workshop summary. Washington, D.C.: National Academies Press; 2006.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_36">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Sawyers</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">The cancer biomarker problem</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>452</VolumeID>
                <IssueID>7187</IssueID>
                <FirstPage>548</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>18385728</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nature06913</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXktFCgtrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sawyers CL. The cancer biomarker problem. Nature 2008;452(7187):548–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_36">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CH</Initials>
                  <FamilyName>Yeon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MD</Initials>
                  <FamilyName>Pegram</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer</ArticleTitle>
                <JournalTitle>Invest New Drugs</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>391</FirstPage>
                <LastPage>409</LastPage>
                <Occurrence Type="PID">
                  <Handle>16133791</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s10637-005-2899-8</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXnvVSqsbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 2005;23(5):391–409.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_36">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Sawyers</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Rational therapeutic intervention in cancer: kinases as drug targets</ArticleTitle>
                <JournalTitle>Curr Opin Genet Dev</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>111</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>11790564</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0959-437X(01)00273-8</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XktFGluw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sawyers CL. Rational therapeutic intervention in cancer: kinases as drug targets. Curr Opin Genet Dev 2002;12(1):111–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_36">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RG</Initials>
                  <FamilyName>Amado</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Wolf</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Peeters</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>1626</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>18316791</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2007.14.7116</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXltlWhsrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(10):1626–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_36">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LV</Initials>
                  <FamilyName>Sequist</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Bell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Lynch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Haber</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>587</FirstPage>
                <LastPage>95</LastPage>
                <Occurrence Type="PID">
                  <Handle>17290067</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2006.07.3585</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXivF2mtLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25(5):587–95.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_36">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SR</Initials>
                  <FamilyName>Morris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Carey</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Gene expression profiling in breast cancer</ArticleTitle>
                <JournalTitle>Curr Opin Oncol</JournalTitle>
                <VolumeID>19</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>547</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>17906450</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/CCO.0b013e3282f0ada3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtFSnu7zI</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Morris SR, Carey LA. Gene expression profiling in breast cancer. Curr Opin Oncol 2007;19(6):547–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_36">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy</ArticleTitle>
                <JournalTitle>Mod Pathol</JournalTitle>
                <VolumeID>17</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>307</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>14739905</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/modpathol.3800050</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol 2004;17(3):307–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_36">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Varadhachary</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Abbruzzese</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Lenzi</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Diagnostic strategies for unknown primary cancer</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>100</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>1776</FirstPage>
                <LastPage>85</LastPage>
                <Occurrence Type="PID">
                  <Handle>15112256</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.20202</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXkt1Sgs70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 2004;100(9):1776–85.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_36">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FJ</Initials>
                  <FamilyName>Bianco</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Wood</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Cher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IJ</Initials>
                  <FamilyName>Powell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Souza</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Pontes</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer</ArticleTitle>
                <JournalTitle>Clin Prostate Cancer</JournalTitle>
                <VolumeID>1</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>242</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>15040883</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3816/CGC.2003.n.006</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bianco FJ Jr, Wood DP Jr, Cher ML, Powell IJ, Souza JW, Pontes JE. Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer. Clin Prostate Cancer 2003;1(4):242–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_36">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>Allsbrook</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MB</Initials>
                  <FamilyName>Amin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LL</Initials>
                  <FamilyName>Egevad</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists</ArticleTitle>
                <JournalTitle>Adv Anat Pathol</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>57</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16462155</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.pap.0000202017.78917.18</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol 2006;13(1):57–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_36">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Graefen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PI</Initials>
                  <FamilyName>Karakiewicz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Cagiannos</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>20</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>951</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>11844816</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.20.4.951</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Graefen M, Karakiewicz PI, Cagiannos I, et al. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol 2002;20(4):951–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_36">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MW</Initials>
                  <FamilyName>Kattan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Zelefsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Kupelian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PT</Initials>
                  <FamilyName>Scardino</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Fuks</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Leibel</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>19</IssueID>
                <FirstPage>3352</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11013275</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3M%2FgvFWmtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000;18(19):3352–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_36">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Stephenson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PT</Initials>
                  <FamilyName>Scardino</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Eastham</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>98</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>715</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>16705126</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djj190</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98(10):715–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_36">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PI</Initials>
                  <FamilyName>Karakiewicz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GC</Initials>
                  <FamilyName>Hutterer</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Predictive models and prostate cancer</ArticleTitle>
                <JournalTitle>Nat Clin Pract</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>82</FirstPage>
                <LastPage>92</LastPage>
              </BibArticle>
              <BibUnstructured>Karakiewicz PI, Hutterer GC. Predictive models and prostate cancer. Nat Clin Pract 2008;5(2):82–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_36">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Lapointe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Higgins</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Gene expression profiling identifies clinically relevant subtypes of prostate cancer</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>101</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>811</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>14711987</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.0304146101</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhsVWhu7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004;101(3):811–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_36">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>True</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Coleman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Hawley</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">A molecular correlate to the Gleason grading system for prostate adenocarcinoma</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>103</VolumeID>
                <IssueID>29</IssueID>
                <FirstPage>10991</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>16829574</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.0603678103</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XnsFentL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>True L, Coleman I, Hawley S, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A 2006;103(29):10991–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_36">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Singh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PG</Initials>
                  <FamilyName>Febbo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Gene expression correlates of clinical prostate cancer behavior</ArticleTitle>
                <JournalTitle>Cancer Cell</JournalTitle>
                <VolumeID>1</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>203</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12086878</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S1535-6108(02)00030-2</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XivVegsbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1(2):203–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_36">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Chin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Reiter</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Molecular markers and prostate cancer prognosis</ArticleTitle>
                <JournalTitle>Clin Prostate Cancer</JournalTitle>
                <VolumeID>3</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>157</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>15636682</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3816/CGC.2004.n.026</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjtFens7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chin JL, Reiter RE. Molecular markers and prostate cancer prognosis. Clin Prostate Cancer 2004;3(3):157–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_36">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Freedland</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">deGregorio F, Sacoolidge JC, et al. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>169</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>1325</FirstPage>
                <LastPage>30</LastPage>
                <Occurrence Type="PID">
                  <Handle>12629353</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.ju.0000054004.08958.f3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXhvFahs70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Freedland SJ, deGregorio F, Sacoolidge JC, et al. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol 2003;169(4):1325–30.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_36">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Naitoh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Murphy</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Low p27 expression predicts poor disease-free survival in patients with prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>159</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>941</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>9474188</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(01)63776-5</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmslOktr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998;159(3):941–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_36">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Mouraviev</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Tahir</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">The role of caveolin-1 in androgen insensitive prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>168</VolumeID>
                <IssueID>4 Pt 1</IssueID>
                <FirstPage>1589</FirstPage>
                <LastPage>96</LastPage>
                <Occurrence Type="PID">
                  <Handle>12352463</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xot1Sqt7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mouraviev V, Li L, Tahir SA, et al. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol 2002;168(4 Pt 1):1589–96.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_36">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Cordon-Cardo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Kotsianti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Verbel</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Improved prediction of prostate cancer recurrence through systems pathology</ArticleTitle>
                <JournalTitle>The Journal of clinical investigation</JournalTitle>
                <VolumeID>117</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>1876</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>17557117</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1172/JCI31399</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXnvVansr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cordon-Cardo C, Kotsianti A, Verbel DA, et al. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 2007;117(7):1876–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_36">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Wheeler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Dai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Frolov</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Ayala</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy</ArticleTitle>
                <JournalTitle>Am J Surg Pathol</JournalTitle>
                <VolumeID>28</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>928</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>15223964</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00000478-200407000-00013</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004;28(7):928–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_36">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K0</Initials>
                  <FamilyName>Wako</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Kawasaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Yamana</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Pathol</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>448</FirstPage>
                <LastPage>54</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1136/jcp.2007.050906</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wako K, Kawasaki T, Yamana K, et al. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008;4:448–54.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_36">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Torlakovic</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Lilleby</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Berner</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>117</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>381</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>15900599</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/ijc.21174</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtFant7rK</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Torlakovic E, Lilleby W, Berner A, et al. Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma. Int J Cancer 2005;117(3):381–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_36">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Torlakovic</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Lilleby</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Torlakovic</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Fossa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Chibbar</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score</ArticleTitle>
                <JournalTitle>Hum Pathol</JournalTitle>
                <VolumeID>33</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>646</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>12152165</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1053/hupa.2002.124033</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xms1Sis7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Torlakovic E, Lilleby W, Torlakovic G, Fossa SD, Chibbar R. Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score. Hum Pathol 2002;33(6):646–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_36">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Bettencourt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Bauer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IA</Initials>
                  <FamilyName>Sesterhenn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FK</Initials>
                  <FamilyName>Mostofi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>McLeod</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Moul</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>156</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>1064</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>8709308</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(01)65703-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK28zitV2luw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996;156(3):1064–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_36">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Cowen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Troncoso</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VS</Initials>
                  <FamilyName>Khoo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>8</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1148</FirstPage>
                <LastPage>54</LastPage>
                <Occurrence Type="PID">
                  <Handle>12006531</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cowen D, Troncoso P, Khoo VS, et al. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res 2002;8(5):1148–54.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_36">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>OJ</Initials>
                  <FamilyName>Halvorsen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Haukaas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Hoisaeter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Akslen</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy</ArticleTitle>
                <JournalTitle>Anticancer Res</JournalTitle>
                <VolumeID>21</VolumeID>
                <FirstPage>4071</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>11911294</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xis1artLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA. Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Res 2001;21(6A):4071–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_36">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Bok</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Bloodborne biomolecular markers in prostate cancer development and progression</ArticleTitle>
                <JournalTitle>Nat Rev Cancer</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>918</FirstPage>
                <LastPage>26</LastPage>
                <Occurrence Type="PID">
                  <Handle>12459730</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nrc951</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XptFCjsbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bok RA, Small EJ. Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer 2002;2(12):918–26.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_36">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ES</Initials>
                  <FamilyName>Leman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GW</Initials>
                  <FamilyName>Cannon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BJ</Initials>
                  <FamilyName>Trock</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">EPCA-2: a highly specific serum marker for prostate cancer</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>69</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>714</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>17445657</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urology.2007.01.097</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Leman ES, Cannon GW, Trock BJ, et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007;69(4):714–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_36">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Nam</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Diamandis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Toi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Serum Human Glandular Kallikrein-2 Protease Levels Predict the Presence of Prostate Cancer Among Men With Elevated Prostate-Specific Antigen</ArticleTitle>
                <JournalTitle>Journal of Clinical Oncology</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1036</FirstPage>
                <Occurrence Type="PID">
                  <Handle>10694554</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3c7mtVOnug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nam R, Diamandis E, Toi A, et al. Serum human glandular Kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 2000;18(5):1036.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_36">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Berruti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Dogliotti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Mosca</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Circulating neuroendocrine markers in patients with prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>88</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2590</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10861438</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(20000601)88:11&lt;2590::AID-CNCR23&gt;3.0.CO;2-D</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3cvisFyrug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88(11):2590–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_36">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Berruti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Mosca</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Tucci</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease</ArticleTitle>
                <JournalTitle>Endocr Relat Cancer</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>109</FirstPage>
                <LastPage>17</LastPage>
                <Occurrence Type="PID">
                  <Handle>15788643</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1677/erc.1.00876</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjsV2lsb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocrine Relat Cancer 2005;12(1):109–17</BibUnstructured>
            </Citation>
            <Citation ID="CR37_36">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Culine</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MEL</Initials>
                  <FamilyName>Demery</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Lamy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Iborra</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Avances</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Pinguet</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>178</VolumeID>
                <FirstPage>844</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>17631339</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2007.05.044</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtValtrnF</Handle>
                </Occurrence>
                <BibComments>(3 Pt 1) discussion 848</BibComments>
              </BibArticle>
              <BibUnstructured>Culine S, El Demery M, Lamy PJ, Iborra F, Avances C, Pinguet F. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007;178(3 Pt 1):844–8; discussion 848.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_36">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YJ</Initials>
                  <FamilyName>Ko</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2511</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>10363963</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjs1yms7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999;59(11):2511–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_36">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Jung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Lein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Stephan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>111</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>783</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>15252851</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/ijc.20314</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXmvVenu7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jung K, Lein M, Stephan C, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004;111(5):783–91</BibUnstructured>
            </Citation>
            <Citation ID="CR40_36">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Armstrong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Garrett-Mayer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YC</Initials>
                  <FamilyName>Ou Yang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>25</IssueID>
                <FirstPage>3965</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>17761981</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2007.11.4769</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007;25(25):3965–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_36">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Armstrong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ES</Initials>
                  <FamilyName>Garrett-Mayer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YC</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Eisenberger</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 Study Analysis</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>21</IssueID>
                <FirstPage>6396</FirstPage>
                <LastPage>403</LastPage>
                <Occurrence Type="PID">
                  <Handle>17975152</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-07-1036</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1CgtbzN</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: a TAX327 Study Analysis. Clin Cancer Res 2007;13(21):6396–403.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_36">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>21</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>1232</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>12663709</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2003.06.100</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21(7):1232–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_36">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>George</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TF</Initials>
                  <FamilyName>Shepard</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>1932</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>11448906</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3MzpslegtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7(7):1932–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_36">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Graff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AS</Initials>
                  <FamilyName>Lalani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): results from the ASCENT trial</ArticleTitle>
                <JournalTitle>Proc Am Soc Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>18S</FirstPage>
                <BibComments>abstract 5074</BibComments>
              </BibArticle>
              <BibUnstructured>Graff J, Lalani AS, Lee S, et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): results from the ASCENT trial. Proc Am Soc Clin Oncol 2007;25(18 S):abstract 5074.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_36">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Humphrey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Picus</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480</ArticleTitle>
                <JournalTitle>Clin Genitourin Cancer</JournalTitle>
                <VolumeID>4</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>269</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>16729910</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3816/CGC.2006.n.006</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xltlejsbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Humphrey PA, Halabi S, Picus J, et al. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer 2006;4(4):269–74</BibUnstructured>
            </Citation>
            <Citation ID="CR46_36">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Balk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YJ</Initials>
                  <FamilyName>Ko</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Biology of prostate-specific antigen</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>21</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>383</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>12525533</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2003.02.083</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVWqs7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21(2):383–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_36">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WJ</Initials>
                  <FamilyName>Catalona</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DS</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TL</Initials>
                  <FamilyName>Ratliff</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1991</Year>
                <ArticleTitle Language="En">Measurement of prostate-specific antigen in serum as a screening test for prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>324</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>1156</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>1707140</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM199104253241702</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3M7oslSksA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324(17):1156–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_36">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Labrie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Dupont</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Suburu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Serum prostate specific antigen as pre-screening test for prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>147</VolumeID>
                <IssueID>3 Pt 2</IssueID>
                <FirstPage>846</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>1371560</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK387mslCgsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Labrie F, Dupont A, Suburu R, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992;147(3 Pt 2):846–51; discussion 851–2.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_36">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MK</Initials>
                  <FamilyName>Brawer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MP</Initials>
                  <FamilyName>Chetner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Beatie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Buchner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Vessella</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PH</Initials>
                  <FamilyName>Lange</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Screening for prostatic carcinoma with prostate specific antigen</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>147</VolumeID>
                <IssueID>3 Pt 2</IssueID>
                <FirstPage>841</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>1371559</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK387mslChuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147(3 Pt 2):841–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_36">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IM</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DK</Initials>
                  <FamilyName>Pauler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Goodman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Prevalence of prostate cancer among men with a prostate-specific antigen level &lt; or =4.0 ng per milliliter</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>350</VolumeID>
                <IssueID>22</IssueID>
                <FirstPage>2239</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>15163773</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa031918</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXksVehsr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level &lt; or =4.0 ng per milliliter. N Engl J Med 2004;350(22):2239–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_36">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Mikolajczyk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KM</Initials>
                  <FamilyName>Marker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LS</Initials>
                  <FamilyName>Millar</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>18</IssueID>
                <FirstPage>6958</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>11559576</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXntFait70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mikolajczyk SD, Marker KM, Millar LS, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61(18):6958–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_36">
              <CitationNumber>52</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>D’Amico</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Moul</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR</Initials>
                  <FamilyName>Carroll</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>96</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>509</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>15069112</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djh086</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>D’Amico AV, Moul JW, Carroll PR, et al. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst 2004;96(7):509–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_36">
              <CitationNumber>53</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Kwak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Jeong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Park</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SE</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>168</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>995</FirstPage>
                <LastPage>1000</LastPage>
                <Occurrence Type="PID">
                  <Handle>12187207</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)64559-4</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002;168(3):995–1000.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_36">
              <CitationNumber>54</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SF</Initials>
                  <FamilyName>Slovin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AS</Initials>
                  <FamilyName>Wilton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Heller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>24 Pt 1</IssueID>
                <FirstPage>8669</FirstPage>
                <LastPage>73</LastPage>
                <Occurrence Type="PID">
                  <Handle>16361552</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-05-1668</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtlWrsb3M</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Slovin SF, Wilton AS, Heller G, Scher HI. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 2005;11(24 Pt 1):8669–73.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_36">
              <CitationNumber>55</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>17</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>3461</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10550143</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3c%2FhvValsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17(11):3461–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_36">
              <CitationNumber>56</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BL</Initials>
                  <FamilyName>Boyanton</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KE</Initials>
                  <FamilyName>Blick</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Stability studies of twenty-four analytes in human plasma and serum</ArticleTitle>
                <JournalTitle>Clin Chem</JournalTitle>
                <VolumeID>48</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>2242</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>12446483</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xptlams7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Boyanton BL Jr, Blick KE. Stability studies of twenty-four analytes in human plasma and serum. Clin Chem 2002;48(12):2242–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_36">
              <CitationNumber>57</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Evans</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JH</Initials>
                  <FamilyName>Livesey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Ellis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TG</Initials>
                  <FamilyName>Yandle</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones</ArticleTitle>
                <JournalTitle>Clin Biochem</JournalTitle>
                <VolumeID>34</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>107</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>11311219</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0009-9120(01)00196-5</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjs1Ogtbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Evans MJ, Livesey JH, Ellis MJ, Yandle TG. Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin Biochem 2001;34(2):107–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_36">
              <CitationNumber>58</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Banks</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Stanley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Cairns</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry</ArticleTitle>
                <JournalTitle>Clin Chem</JournalTitle>
                <VolumeID>51</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>1637</FirstPage>
                <LastPage>49</LastPage>
                <Occurrence Type="PID">
                  <Handle>16002455</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1373/clinchem.2005.051417</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXps1yktbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Banks RE, Stanley AJ, Cairns DA, et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 2005;51(9):1637–49.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_36">
              <CitationNumber>59</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SY</Initials>
                  <FamilyName>Hsieh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YH</Initials>
                  <FamilyName>Pan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling</ArticleTitle>
                <JournalTitle>Proteomics</JournalTitle>
                <VolumeID>6</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>3189</FirstPage>
                <LastPage>98</LastPage>
                <Occurrence Type="PID">
                  <Handle>16586434</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pmic.200500535</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XlsFagt7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hsieh SY, Chen RK, Pan YH, Lee HL. Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling. Proteomics 2006;6(10):3189–98.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_36">
              <CitationNumber>60</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NL</Initials>
                  <FamilyName>Anderson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NG</Initials>
                  <FamilyName>Anderson</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">The human plasma proteome: history, character, and diagnostic prospects</ArticleTitle>
                <JournalTitle>Mol Cell Proteomics</JournalTitle>
                <VolumeID>1</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>845</FirstPage>
                <LastPage>67</LastPage>
                <Occurrence Type="PID">
                  <Handle>12488461</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/mcp.R200007-MCP200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXht1Ciug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1(11):845–67.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_36">
              <CitationNumber>61</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Rabilloud</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains</ArticleTitle>
                <JournalTitle>Proteomics</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>3</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>11788986</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1615-9861(200201)2:1&lt;3::AID-PROT3&gt;3.0.CO;2-R</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XosFyrtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rabilloud T. Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics 2002;2(1):3–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_36">
              <CitationNumber>62</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WH</Initials>
                  <FamilyName>McDonald</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Yates</FamilyName>
                  <Suffix>III</Suffix>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Shotgun proteomics: integrating technologies to answer biological questions</ArticleTitle>
                <JournalTitle>Curr Opin Mol Ther</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>302</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12870441</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXmtVWqtLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>McDonald WH, Yates JR III. Shotgun proteomics: integrating technologies to answer biological questions. Curr Opin Mol Ther 2003;5(3):302–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_36">
              <CitationNumber>63</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DK</Initials>
                  <FamilyName>Han</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Overcoming the dynamic range problem in mass spectrometry-based shotgun proteomics</ArticleTitle>
                <JournalTitle>Expert Rev Proteomics</JournalTitle>
                <VolumeID>3</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>611</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>17181475</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1586/14789450.3.6.611</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhvFGqtrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wu L, Han DK. Overcoming the dynamic range problem in mass spectrometry-based shotgun proteomics. Expert Rev Proteomics 2006;3(6):611–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_36">
              <CitationNumber>64</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Gong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Different immunoaffinity fractionation strategies to characterize the human plasma proteome</ArticleTitle>
                <JournalTitle>J Proteome Res</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1379</FirstPage>
                <LastPage>87</LastPage>
                <Occurrence Type="PID">
                  <Handle>16739989</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1021/pr0600024</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XktVerurk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gong Y, Li X, Yang B, et al. Different immunoaffinity fractionation strategies to characterize the human plasma proteome. J Proteome Res 2006;5(6):1379–87.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_36">
              <CitationNumber>65</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Liu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WJ</Initials>
                  <FamilyName>Qian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HM</Initials>
                  <FamilyName>Mottaz</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry</ArticleTitle>
                <JournalTitle>Mol Cell Proteomics</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2167</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>16854842</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/mcp.T600039-MCP200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtlSis7jO</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Liu T, Qian WJ, Mottaz HM, et al. Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics 2006;5(11):2167–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_36">
              <CitationNumber>66</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Pieper</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Q</Initials>
                  <FamilyName>Su</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Gatlin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ST</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NL</Initials>
                  <FamilyName>Anderson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Steiner</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome</ArticleTitle>
                <JournalTitle>Proteomics</JournalTitle>
                <VolumeID>3</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>422</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>12687610</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pmic.200390057</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXjtVaisrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pieper R, Su Q, Gatlin CL, Huang ST, Anderson NL, Steiner S. Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 2003;3(4):422–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_36">
              <CitationNumber>67</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DE</Initials>
                  <FamilyName>Kalume</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Molina</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Pandey</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Tackling the phosphoproteome: tools and strategies</ArticleTitle>
                <JournalTitle>Curr Opin Chem Biol</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>64</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12547428</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S1367-5931(02)00009-1</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXltlaqtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kalume DE, Molina H, Pandey A. Tackling the phosphoproteome: tools and strategies. Curr Opin Chem Biol 2003;7(1):64–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_36">
              <CitationNumber>68</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Mann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ON</Initials>
                  <FamilyName>Jensen</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Proteomic analysis of post-translational modifications</ArticleTitle>
                <JournalTitle>Nat Biotechnol</JournalTitle>
                <VolumeID>21</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>255</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>12610572</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nbt0303-255</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXhsFajsro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol 2003;21(3):255–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_36">
              <CitationNumber>69</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EC</Initials>
                  <FamilyName>Yi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>XJ</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">High throughput quantitative analysis of serum proteins using glycopeptide capture and liquid chromatography mass spectrometry</ArticleTitle>
                <JournalTitle>Mol Cell Proteomics</JournalTitle>
                <VolumeID>4</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>144</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="PID">
                  <Handle>15608340</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/mcp.M400090-MCP200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhang H, Yi EC, Li XJ, et al. High throughput quantitative analysis of serum proteins using glycopeptide capture and liquid chromatography mass spectrometry. Mol Cell Proteomics 2004;4(2):144–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_36">
              <CitationNumber>70</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Fenn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Mann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CK</Initials>
                  <FamilyName>Meng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SF</Initials>
                  <FamilyName>Wong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Whitehouse</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">Electrospray ionization for mass spectrometry of large biomolecules</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>246</VolumeID>
                <IssueID>4926</IssueID>
                <FirstPage>64</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>2675315</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.2675315</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXmtFWhs7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989;246(4926):64–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_36">
              <CitationNumber>71</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Karas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Hillenkamp</FamilyName>
                </BibAuthorName>
                <Year>1988</Year>
                <ArticleTitle Language="En">Laser desorption ionization of proteins with molecular masses exceeding 10, 000 daltons</ArticleTitle>
                <JournalTitle>Anal Chem</JournalTitle>
                <VolumeID>60</VolumeID>
                <IssueID>20</IssueID>
                <FirstPage>2299</FirstPage>
                <LastPage>301</LastPage>
                <Occurrence Type="PID">
                  <Handle>3239801</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1021/ac00171a028</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1cXlsVGmu7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem 1988;60(20):2299–301.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_36">
              <CitationNumber>72</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Katz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Mallick</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DB</Initials>
                  <FamilyName>Agus</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">A perspective on protein profiling of blood</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>96</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>477</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>16104895</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1464-410X.2005.05669.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtFSjur7P</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Katz JE, Mallick P, Agus DB. A perspective on protein profiling of blood. BJU Int 2005;96(4):477–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_36">
              <CitationNumber>73</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Aebersold</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Mann</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Mass spectrometry-based proteomics</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>422</VolumeID>
                <IssueID>6928</IssueID>
                <FirstPage>198</FirstPage>
                <LastPage>207</LastPage>
                <Occurrence Type="PID">
                  <Handle>12634793</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nature01511</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXhvFKgs7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422(6928):198–207.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_36">
              <CitationNumber>74</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Luethy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DE</Initials>
                  <FamilyName>Kessner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Katz</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Precursor-ion mass re-estimation improves peptide identification on hybrid instruments</ArticleTitle>
                <JournalTitle>J Proteome Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>4031</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>18707148</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1021/pr800307m</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXpvVyjsrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Luethy R, Kessner DE, Katz JE, et al. Precursor-ion mass re-estimation improves peptide identification on hybrid instruments. J Proteome Res 2008;7(9):4031–9</BibUnstructured>
            </Citation>
            <Citation ID="CR75_36">
              <CitationNumber>75</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WA</Initials>
                  <FamilyName>Tao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Aebersold</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Advances in quantitative proteomics via stable isotope tagging and mass spectrometry</ArticleTitle>
                <JournalTitle>Curr Opin Biotechnol</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>110</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>12566010</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0958-1669(02)00018-6</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXps1WltQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tao WA, Aebersold R. Advances in quantitative proteomics via stable isotope tagging and mass spectrometry. Current Opin Biotechnol 2003;14(1):110–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_36">
              <CitationNumber>76</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Unlu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Morgan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Minden</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Difference gel electrophoresis: a single gel method for detecting changes in protein extracts</ArticleTitle>
                <JournalTitle>Electrophoresis</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2071</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>9420172</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/elps.1150181133</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXnvVCns70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997;18(11):2071–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_36">
              <CitationNumber>77</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>MacCoss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Toth</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DE</Initials>
                  <FamilyName>Matthews</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Evaluation and optimization of ion-current ratio measurements by selected-ion-monitoring mass spectrometry</ArticleTitle>
                <JournalTitle>Anal Chem</JournalTitle>
                <VolumeID>73</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>2976</FirstPage>
                <LastPage>84</LastPage>
                <Occurrence Type="PID">
                  <Handle>11467543</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1021/ac010041t</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjsVOksLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>MacCoss MJ, Toth MJ, Matthews DE. Evaluation and optimization of ion-current ratio measurements by selected-ion-monitoring mass spectrometry. Anal Chem 2001;73(13):2976–84.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_36">
              <CitationNumber>78</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Keshishian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Addona</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Burgess</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Kuhn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Carr</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution</ArticleTitle>
                <JournalTitle>Mol Cell Proteomics</JournalTitle>
                <VolumeID>6</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>2212</FirstPage>
                <LastPage>29</LastPage>
                <Occurrence Type="PID">
                  <Handle>17939991</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/mcp.M700354-MCP200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXksF2hsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2007;6(12):2212–29</BibUnstructured>
            </Citation>
            <Citation ID="CR79_36">
              <CitationNumber>79</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Stahl-Zeng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Lange</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Ossola</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites</ArticleTitle>
                <JournalTitle>Mol Cell Proteomics</JournalTitle>
                <VolumeID>6</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>1809</FirstPage>
                <LastPage>17</LastPage>
                <Occurrence Type="PID">
                  <Handle>17644760</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/mcp.M700132-MCP200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1WksbvN</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Stahl-Zeng J, Lange V, Ossola R, et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol Cell Proteomics 2007;6(10):1809–17.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_36">
              <CitationNumber>80</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BL</Initials>
                  <FamilyName>Adam</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Qu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Davis</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>62</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>3609</FirstPage>
                <LastPage>14</LastPage>
                <Occurrence Type="PID">
                  <Handle>12097261</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XltF2jt7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62(13):3609–14.</BibUnstructured>
            </Citation>
            <Citation ID="CR81_36">
              <CitationNumber>81</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EF</Initials>
                  <FamilyName>Petricoin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Ardekani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>Hitt</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Use of proteomic patterns in serum to identify ovarian cancer</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>359</VolumeID>
                <IssueID>9306</IssueID>
                <FirstPage>572</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>11867112</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0140-6736(02)07746-2</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XhsFansbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359(9306):572–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_36">
              <CitationNumber>82</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EF</Initials>
                  <FamilyName>Petricoin</FamilyName>
                  <Suffix>III</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DK</Initials>
                  <FamilyName>Ornstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CP</Initials>
                  <FamilyName>Paweletz</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Serum proteomic patterns for detection of prostate cancer</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>94</VolumeID>
                <IssueID>20</IssueID>
                <FirstPage>1576</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>12381711</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/94.20.1576</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XovFSrurs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petricoin EF III, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94(20):1576–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_36">
              <CitationNumber>83</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>OJ</Initials>
                  <FamilyName>Semmes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Feng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BL</Initials>
                  <FamilyName>Adam</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility</ArticleTitle>
                <JournalTitle>Clin Chem</JournalTitle>
                <VolumeID>51</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>102</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>15613711</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1373/clinchem.2004.038950</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXlt1yntw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Semmes OJ, Feng Z, Adam BL, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51(1):102–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_36">
              <CitationNumber>84</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Sorace</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Zhan</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">A data review and re-assessment of ovarian cancer serum proteomic profiling</ArticleTitle>
                <JournalTitle>BMC Bioinformatics</JournalTitle>
                <VolumeID>4</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>24</FirstPage>
                <Occurrence Type="PID">
                  <Handle>12795817</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1186/1471-2105-4-24</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003;4(1):24.</BibUnstructured>
            </Citation>
            <Citation ID="CR85_36">
              <CitationNumber>85</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Sardana</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Marshall</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EP</Initials>
                  <FamilyName>Diamandis</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium</ArticleTitle>
                <JournalTitle>Clin Chem</JournalTitle>
                <VolumeID>53</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>429</FirstPage>
                <LastPage>37</LastPage>
                <Occurrence Type="PID">
                  <Handle>17259234</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1373/clinchem.2006.077370</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXis1Wnsrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sardana G, Marshall J, Diamandis EP. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. Clin Chem 2007;53(3):429–37.</BibUnstructured>
            </Citation>
            <Citation ID="CR86_36">
              <CitationNumber>86</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DB</Initials>
                  <FamilyName>Martin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Gifford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Wright</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>347</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="PID">
                  <Handle>14729644</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-03-2062</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXkslyrsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Martin DB, Gifford DR, Wright ME, et al. Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 2004;64(1):347–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR87_36">
              <CitationNumber>87</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Gross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Top</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Laux</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>1979</FirstPage>
                <LastPage>86</LastPage>
                <Occurrence Type="PID">
                  <Handle>17404077</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-06-1156</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXjs12rsbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gross M, Top I, Laux I, et al. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res 2007;13(7):1979–86.</BibUnstructured>
            </Citation>
            <Citation ID="CR88_36">
              <CitationNumber>88</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KM</Initials>
                  <FamilyName>Bhat</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Setaluri</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Microtubule-associated proteins as targets in cancer chemotherapy</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>2849</FirstPage>
                <LastPage>54</LastPage>
                <Occurrence Type="PID">
                  <Handle>17504982</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-06-3040</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXlt1Krsrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 2007;13(10):2849–54.</BibUnstructured>
            </Citation>
            <Citation ID="CR89_36">
              <CitationNumber>89</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Jasavala</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Martinez</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Thumar</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Identification of putative androgen receptor interaction protein modules: cytoskeleton and endosomes modulate androgen receptor signaling in prostate cancer cells</ArticleTitle>
                <JournalTitle>Mol Cell Proteomics</JournalTitle>
                <VolumeID>6</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>252</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>17052974</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXitVOitrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jasavala R, Martinez H, Thumar J, et al. Identification of putative androgen receptor interaction protein modules: cytoskeleton and endosomes modulate androgen receptor signaling in prostate cancer cells. Mol Cell Proteomics 2007;6(2):252–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR90_36">
              <CitationNumber>90</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>White</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>65</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>3081</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>15833837</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjt1yksb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lin B, White JT, Lu W, et al. Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res 2005;65(8):3081–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR91_36">
              <CitationNumber>91</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LC</Initials>
                  <FamilyName>Tu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Yan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Hood</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Proteomics analysis of the interactome of N-myc downstream regulated gene 1 and its interactions with the androgen response program in prostate cancer cells</ArticleTitle>
                <JournalTitle>Mol Cell Proteomics</JournalTitle>
                <VolumeID>6</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>575</FirstPage>
                <LastPage>88</LastPage>
                <Occurrence Type="PID">
                  <Handle>17220478</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/mcp.M600249-MCP200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXksVKgtb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tu LC, Yan X, Hood L, Lin B. Proteomics analysis of the interactome of N-myc downstream regulated gene 1 and its interactions with the androgen response program in prostate cancer cells. Mol Cell Proteomics 2007;6(4):575–88.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
